Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in Brazil

from PharmacoEconomics – Open at http://bit.ly/2Ehi6rn on February 27, 2019 at 06:13PM Abstract Background Health costs are the main hindrances for expanding community mental health services. Exploring patient profiles and cost predictors may be useful for optimising financial resources. However, the deinstitutionalisation process may burden health budgets in terms of supporting multiple community services based […]

Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

from PharmacoEconomics – Open at http://bit.ly/2T4MCPH on February 27, 2019 at 06:13PM Abstract Background Nivolumab with ipilimumab (the Regimen) is the first immuno-oncology combination treatment to demonstrate long-term clinical benefit for advanced melanoma patients. We evaluated the cost effectiveness of the Regimen in this population, with and without the availability of overall survival (OS) data. […]

Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease

from PharmacoEconomics – Open at http://bit.ly/2El8ZGp on February 27, 2019 at 06:13PM Abstract Background and objective Peripheral arterial disease (PAD) is a common condition, in which atherosclerotic narrowing in the arteries restricts blood supply to the leg muscles. In order to support future model-based economic evaluations comparing methods of diagnosis in this area, a systematic […]

Report: Pharma Execs Largely Dodged Questions

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2T1Oicy on February 27, 2019 at 02:47PM Pharmaceutical executives during Tuesday’s Senate Finance Committee Hearing mostly dodged key questions, and responded with answers tattered by years of use, according to a STAT report. While top executives representing Merck, Pfizer, AstraZeneca, Johnson & Johnson, AbbVie, Sanofi and Bristol-Myers Squibb […]

Fendrick, Klein Back Drug Rebate Proposal

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2EkBHHr on February 27, 2019 at 02:47PM The Trump administration’s proposal to eliminate pharma-to-PBM rebates in Medicare Part D and Medicaid managed care organizations has the potential to “significantly lower out-of-pocket prescription drug costs,” the authors of a recent opinion piece published on the Morning Consult write. The […]

Real-World Evidence and Value-Based Contracting – Swipe Left or Swipe Right?

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2Nu1BfZ on February 27, 2019 at 01:47PM From HealthEconomics.Com’s official blog As biopharma makes the shift toward a personalized healthcare system, it is also transitioning towards a pipeline full of innovative, high-cost therapies. We are moving to a value-based system, with two of the biggest ideas for this […]

Social learning, influence, and ethnomedicine: Individual, neighborhood and social network influences on attachment to an ethnomedical cultural model in rural Senegal

from Social Science & Medicine at http://bit.ly/2SuQjsF on February 27, 2019 at 11:01AM Publication date: Available online 27 February 2019 Source: Social Science & Medicine Author(s): John Sandberg, Steven Rytina, Valerie Delaunay, Laetitia Douillot, Yacine Boujija, Sadio Ba Gning, Simona Bignami, Cheikh Sokhna, Loubna Belaid, Insa Diouf, Babak Fatouhi, Abdourahmane Senghor Abstract The preference in […]

Social capital, social movements and global public health: Fighting for health-enabling contexts in marginalised settings

from Social Science & Medicine at http://bit.ly/2XsvMbZ on February 27, 2019 at 11:01AM Publication date: Available online 26 February 2019 Source: Social Science & Medicine Author(s): Catherine Campbell Abstract Research linking health and social capital is often cited in relation to global public health policies and programmes that mobilise local community participation in health promotion […]

Parents’ healthcare-seeking behavior for their children among the climate-related displaced population of rural Bangladesh

from Social Science & Medicine at http://bit.ly/2SqQ5Tr on February 27, 2019 at 11:01AM Publication date: Available online 26 February 2019 Source: Social Science & Medicine Author(s): Md Rabiul Haque, Nick Parr, Salut Muhidin Abstract In Bangladesh climate change has contributed to a massive displacement of people. This study examines the effects of climate-related displacement, socioeconomic […]

The food security and nutrition crisis in Venezuela

from Social Science & Medicine at http://bit.ly/2XpQclI on February 27, 2019 at 11:01AM Publication date: Available online 26 February 2019 Source: Social Science & Medicine Author(s): Shannon Doocy, Mija-Tesse Ververs, Paul Spiegel, Chris Beyrer Abstract As Venezuela’s economic and political crises continues to evolve, hyperinflation, declining food production and food shortages are contributing to the […]

Colin Angus to present at the Health Economics & Evidence Synthesis (HEES) Group Seminar Series

from Health Economics and Decision Science Blog @ ScHARR at http://bit.ly/2TkxbC5 on February 27, 2019 at 08:00AM Colin Angus is delivering the next Health Economics & Evidence Synthesis (HEES) Group Seminar Series. His talk is on ‘Modelling the impact on health, healthcare costs and health inequalities of Screening and Brief Intervention programmes’. Further details are […]

Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial

from PharmacoEconomics at http://bit.ly/2XsBwSP on February 27, 2019 at 02:33AM Abstract Background and Objective Population-level endoscopic screening for esophageal cancer has been conducted in China for years. In this study, we aim to provide an updated and precise cost estimation for esophageal cancer screening based on a randomized controlled trial in a high-risk area in […]

AstraZeneca CEO Urges Government Action on Drug Pricing

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2H4J5tu on February 26, 2019 at 09:22PM While fellow pharmaceutical executives urged policymakers not to intervene in drug pricing during a Senate Finance Committee hearing Tuesday, Feb. 26, AstraZeneca’s chief executive went the opposite direction. According to rolling updates from MM&M, Pascal Soriot pleaded with Senators to take […]

A Multi-Stakeholder Consensus-Driven Research Agenda for Better Understanding and Supporting the Emotional Impact of Harmful Events on Patients and Families

from RAND Research Topic: Health and Health Care at http://bit.ly/2H539vQ on February 26, 2019 at 09:15PM Background The nature and consequences of patient and family emotional harm stemming from preventable medical error, such as losing a loved one or surviving serious medical injury, is poorly understood. Patients and families, clinicians, social scientists, lawyers, and foundation/policy […]

Tuft’s CEVR Hiring Grad School Students for Summer Internship

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2TlQhYw on February 26, 2019 at 08:52PM Tufts Medical Center’s Center for the Evaluation of Value and Risk in Health (CEVR) is hiring five to six grad school students to assist over the summer with extracting key information from cost-effectiveness articles. According to CEVR’s website, the paid internship […]

Article: OBC Puts Patient First

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2IF7mIK on February 26, 2019 at 08:52PM Outcomes-based contracting puts the patient first, Model N’s Nate Taninecz writes in an article published on Pharmaceutical Executive, describing it as “less is more.” Taninecz in his article writes that outcomes-based contracts give patients “the best possible treatment,” while also offering […]

Pharma Execs Warn Against Heavy Congressional Intervention for Drug Prices

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2TjzG7E on February 26, 2019 at 08:52PM As the Senate Finance Committee put the pressure on representatives from seven of the top pharmaceutical companies over rising drug prices, the executives warned legislators that any intervention could pose significant problems, the Associated Press reports. Merck CEO Kenneth Frazier during […]

Peschin: ICER’s Methodology is ‘Unscientific and Discriminatory’

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2NtreNO on February 26, 2019 at 06:51PM The Institute for Clinical and Economic Review’s (ICER) approach to generating cost-effectiveness reviews is “unscientific and discriminatory,” Alliance for Aging Research President and CEO Susan Peschin writes in a column published on The Hill. Peschin writes that ICER’s main metric, the […]

ISPOR’s Women in HEOR Launch LinkedIn Group

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2T2q2Hl on February 26, 2019 at 06:21PM In an effort to facilitate discussions involving the advancement of women in leadership positions in health economics and outcomes research (HEOR), the International Society for Pharmacoeconomics and Outcomes Research’s Women in HEOR has launched a LinkedIn discussion group. ISPOR launched the […]